2021
DOI: 10.1007/s10147-021-02061-0
|View full text |Cite
|
Sign up to set email alerts
|

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis

Abstract: Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of pretreatment clinical characteristics and hematologic biomarkers for prognosticating response to pembrolizumab in patients with metastatic UC. PUBMED®, Web of Science™, and Scopus® databases were searched for articles published before May 2021 according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
22
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(24 citation statements)
references
References 72 publications
2
22
0
Order By: Relevance
“…All previous meta-analyses about immunotherapy and NLR focused on the impact of baseline NLR on prognosis [ 60 , 61 , 62 , 63 , 64 , 65 ]. Although a small part of the meta-analyses included a few studies addressing the dynamics of NLR, they did not conduct quantitative analysis and did not arrive at a specific conclusion [ 60 , 61 ].…”
Section: Discussionmentioning
confidence: 99%
“…All previous meta-analyses about immunotherapy and NLR focused on the impact of baseline NLR on prognosis [ 60 , 61 , 62 , 63 , 64 , 65 ]. Although a small part of the meta-analyses included a few studies addressing the dynamics of NLR, they did not conduct quantitative analysis and did not arrive at a specific conclusion [ 60 , 61 ].…”
Section: Discussionmentioning
confidence: 99%
“…Along with the search for histological biomarkers, hematological biomarkers have also been explored (5). Pretreatment baseline hematological parameters, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), have been studied (16)(17)(18)(19).…”
Section: Discussionmentioning
confidence: 99%
“…Unfortunately, only a minority of patients benefits from pembrolizumab. Establishing biomarkers to predict the efficacy of this drug is therefore an important challenge ( 5 ).…”
Section: Introductionmentioning
confidence: 99%
“…Already established prognostic factors in RCC are pathologic stage, lymph node status, and histologic grade [34]. For metastasized UC, the presence of liver metastasis, poor performance status, high C-reactive protein, and high neutrophil-lymphocyte ratio were independent prognostic factors under immunotherapy [35]. It would be interesting to study whether LSMM could be added as another independent prognostic factor.…”
Section: Discussionmentioning
confidence: 99%
“…The importance of muscle mass quantification based on imaging has a great clinical relevance. As such, one important point for the diagnosis of malnutrition is the LSMM assessment with the proposed threshold values [35, 36]. In clinical routine, early diagnosis of malnutrition could provide better nutritional support for advanced cancer patients as part of multimodal therapeutic approaches to maintain or build skeletal muscle mass [35, 36].…”
Section: Discussionmentioning
confidence: 99%